MDIC in the News: Wilson Sonsini Lifesciences Biannual Report

Cyrano Therapeutics CEO Rick Geoffrion delves into the transformative impact of the Early Feasibility Studies (EFS) Program on the medical device industry. Established by the FDA in 2013, the EFS Program has allowed U.S.-based medtech innovators to conduct early-stage clinical trials domestically, reducing the need for lengthy overseas trials. Geoffrion highlights the program’s role in expediting patient access to pioneering treatments and fostering collaboration among key stakeholders, including the FDA and MDIC. MDIC’s initiatives, such as the Master Clinical Trial Agreement, have significantly streamlined processes, further enhancing the EFS framework.

Read the full article to explore how EFS is reshaping the landscape for medical device innovation.